Home › Kidney Cancer (Renal Cell Carcinoma) › NCT06376669

Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma

Prospective Phase II Study of Stereotactic Body Proton Therapy for Treatment of PrimAry Renal Cell Carcinoma (SPARE)

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Age ≥ 18 years
2. Biopsy proven renal cell carcinoma.
3. No clinical or radiographic evidence of metastatic disease.
4. Not a candidate for surgical treatment or local ablative procedures.
5. Subjects are able to undergo either an MRI or administration of contrast agent for CT.

Exclusion Criteria:

1. Prior history of radiation treatment with overlapping fields.
2. Patients with proven metastatic disease.
3. Female subjects who are pregnant or planning to become pregnant during the treatment.

About the study

This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.

What is being tested

• Proton Stereotactic Body Radiation therapy (SBRT) (radiation)

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Participants: 20 · Started: Feb 25, 2025

Contact the study team

• Sherif Shaaban · Phone: 202-919-2523
• Ryan Manuel · Phone: 410-955-4261

Official record on ClinicalTrials.gov — NCT06376669

Locations in the U.S.

Conditions

• Kidney Cancer (Renal Cell Carcinoma)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.